Você está deixando o Portal Médico GSK

Você está prestes a deixar o site da GSK. Ao clicar neste link, você será direcionado a um site que não pertence ou é controlado pela GSK. Portanto, a GSK não é responsável por demais conteúdos presentes neste site.

Continuar

Voltar

Tratamento de pacientes ART-naive

Nosso time de infectologistas apresenta os diferentes cenários de início de tratamento em pacientes virgens de TARV.

   

  • 1.  WORLD HEALTH ORGANIZATION (WHO). Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2016. Disponível em: <http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1>. Acesso em: 30 out. 2018.

    2. WORLD HEALTH ORGANIZATION (WHO). Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Disponível em: <http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18-eng.pdf?ua=1>. Acesso em: 30 out. 2018.

    3.  EUROPEAN AIDS CLINICAL SOCIETY (EACS). Guidelines. Version 9.1. Disponível em: <http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf>. Acesso em: 30 out. 2018.

    4. BRITISH HIV ASSOCIATION (BHIVA). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Disponível em: <https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines-2016-interim-update.pdf>. Acesso em: 30 out. 2018.

    5.  DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Disponível em: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf>. Acesso em: 30 out. 2018.

    6. SAAG, MS. et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA; 320(4):379-396, 2018.

    7. SNEDECOR, SJ. et al. The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV Infected Patients. Plos One; 8(8):e72784, 2013.